Skip to main content
European Commission logo
polski polski
CORDIS - Wyniki badań wspieranych przez UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

Feasibility Study for the introduction into pre-clinical study domain of the first-of-a-kind Multi Organ On Device (MOOD) technology

Cel

Advances in molecular biology have significantly increased the understanding of the biology of different diseases. Nevertheless, these advances are not fully translated yet into improved treatments for patients, specifically for what pertains to the oncological disorders. One of main reasons for this shortcoming is the lack of reliable in vivo models that accurately predict drug efficacy and toxicity, so to translate these results from preclinical studies to the clinic. In present project we address the major challenge of the preclinical stage in drug development, by offering a proprietary Multi-Organ-On-Device (MOOD), being an advanced fluidic multi-chamber bioreactor, a 3D model of breast cancer tissue cultured onto a membrane mimicking the blood vessel barrier, which jointly reproduce the physio mimetic environment of the cancer disease. In this way, MOOD technology enables the execution of standard pre-clinical assays, such as tumor cell migration and intravasation, drug efficacy and toxicity assays, thus bypassing unreliable, costly and ethically relevant mice studies. The validation of the MOOD device paves the way for the replacement, reduction and refinement (3Rs) of animal studies on global scale, allowing for dramatic cost reduction in the pre-clinical stage and for accelerated time to market for pharmaceutical companies and CROs. The objectives of this feasibility study will be the deep understanding of the market and its technological and economic requirements, so to properly stream line the industrialization of MOOD platform. We expect our MOOD technology to exert a disruptively beneficial impact on drug development process and thus, human health and national economies.

Zaproszenie do składania wniosków

H2020-EIC-SMEInst-2018-2020

Zobacz inne projekty w ramach tego zaproszenia

Szczegółowe działanie

H2020-SMEInst-2018-2020-1

Koordynator

REACT4LIFE SPA
Wkład UE netto
€ 50 000,00
Adres
VIA DOMENICO FIASELLA 1
16121 Genova
Włochy

Zobacz na mapie

MŚP

Organizacja określiła się jako MŚP (firma z sektora małych i średnich przedsiębiorstw) w czasie podpisania umowy o grant.

Tak
Region
Nord-Ovest Liguria Genova
Rodzaj działalności
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Linki
Koszt całkowity
€ 71 429,00